Market Overview

SimonMed Deploys ClearRead CT Enterprise Wide


SimonMed Imaging, one of the largest outpatient physician radiology
groups in the United States, has selected Riverain Technologies'
advanced AI application, ClearRead
, to further enhance its growing lung cancer screening program.
ClearRead CT employs a patented vessel suppression technology and was
the first FDA cleared radiological device approved for all nodule types,
including part-solid and ground glass. ClearRead CT is proven to improve
both nodule detection accuracy and nodule search efficiency, has studies
published in multiple peer review journals, and is in daily use at
several leading healthcare institutions.

ClearRead CT was successfully integrated and demonstrated as part of an
extensive trial at SimonMed. The SimonMed enterprise consists of a
distributed, multi-center, network with high exam volumes.

"SimonMed is extremely pleased to be working with Riverain Technologies,
a pioneer in using AI for better detection and characterization of lung
lesions allowing for more reliable diagnosis and treatment," said Dr.
John Simon, CEO of SimonMed. "SimonMed has always been on the forefront
of technology and recognizes that AI is critical to the future of
radiology as we continue to drive toward better patient outcomes."

"We are thrilled that SimonMed chose Riverain's ClearRead CT to enhance
their lung cancer screening program, and are honored to be working with
such a talented group of radiologists," said Steve Worrell, CEO of
Riverain Technologies. "We look forward to our continued relationship
with them as we further improve ClearRead CT and develop new
applications in radiology."

Riverain Technologies

Riverain Technologies is a clinical AI software innovator that develops
solutions to aid clinicians in the early detection of disease. For more
information visit:

View Comments and Join the Discussion!